CD8A and cancer: Our results conclude that peptide vaccination regimen capable of inducing concurrent multivalent CD8 T-cell responses specific to more than one antigen could circumvent the potential drawbacks of single-peptide-based vaccines, and that the sufficient endurance of PD1 blockade amplified significantly the effectiveness of cancer vaccines comprising multi-peptides as well as single-peptide.